In a research review, the FDA and the National Institutes of Health (NIH) stressed the importance of promoting innovation in smoking cessation products, noting that the long-term health effects of vapes should be thoroughly studied, including long-term health outcomes and toxicology studies.
FDA and NIH support smoking cessation product innovation
According to the data of the US Drug Administration (FDA) website released news on October 15, the Annals of Internal Medicine (Annals of Internal Medicine) in the US Institutes of Health published a new review, (NIH) article authors updated the regulatory approach to smoking cessation treatment, It also summarizes innovative treatment goals, research gaps, and development opportunities, as well as FDA leadership’s emphasis on advancing innovative recommendations for smoking cessation treatment development. They emphasize the importance of actively engaging with stakeholders such as clinicians, academia, industry, public health agencies, and patient teams.
Emphasize attention to vape research needs
Nearly half a million people die each year in the United States from smoking, and more than 28 million adults smoke in the United States each year. While most smokers say they want to quit, only 31 percent of those who intend to quit receive counseling or medication, and less than 8 percent of smokers effectively quit each year.
Commenters made comments on addressing this issue, including comments from the FDA’s 2023 2008 Nicotine Replacement Therapy Guidelines. To stimulate innovation in smoking cessation product development, the authors point out that in addition to focusing on smoking cessation, valuable research destinations such as reducing clinically valuable smoking should also be considered in smoking cessation trials, especially if this reduction increases the probability of eventual smoking cessation.
The authors also highlight the urgent need for more in-depth research on vapes, including long-term health outcomes and rigorous toxicological studies. In addition, they discussed ongoing NIH and FDA projects that specifically include people who are underrepresented in historical research experiments.
This comment comes ahead of the joint FDA and NIH public meeting, which will take place on October 21 from 9:00 a.m. to 4:30 p.m. Et.
